Pamidronic acid
Based on 1 publication(s) in Google Scholar
Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.05%
- CAS 番号: 40391-99-9
- 分子式: C3H11NO7P2
- 分子量:235.07
-
保管条件:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-COVID-19 Compound Library
HY-L052
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Rare Diseases Drug Library
HY-L102
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Pattern Recognition Receptors Library
HY-L237
-
Lactylation Compound Library
HY-L249
MedChemExpress（MCE）の使用を引用している文献 Pamidronic acid
More
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 13762 | IC50 |
33.6 μM
Compound: 38
|
Antiproliferative activity against rat 13762 cell line
Antiproliferative activity against rat 13762 cell line
|
[PMID: 16970405] |
| HepG2 | IC50 |
>200 μM
Compound: Pamidronate
|
Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR
Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR
|
[PMID: 20457823] |
| HFF | IC50 |
38 μM
Compound: 20
|
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
|
[PMID: 15857119] |
| MCF7 | IC50 |
141 μM
Compound: 38
|
Antiproliferative activity against human MCF7 cell line by MTT assay
Antiproliferative activity against human MCF7 cell line by MTT assay
|
[PMID: 16970405] |
| MCF7 | IC50 |
22.9 μM
Compound: Pamidronate
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
|
[PMID: 33132173] |
| NCI-H460 | IC50 |
71.8 μM
Compound: 38
|
Antiproliferative activity against human NCI-H460 cell line by MTT assay
Antiproliferative activity against human NCI-H460 cell line by MTT assay
|
[PMID: 16970405] |
| SF-268 | IC50 |
408 μM
Compound: 38
|
Antiproliferative activity against human SF-268 cell line by MTT assay
Antiproliferative activity against human SF-268 cell line by MTT assay
|
[PMID: 16970405] |
| T-cell | EC50 |
43 μM
Compound: 1
|
Effective concentration against human Gamma delta T cells
Effective concentration against human Gamma delta T cells
|
[PMID: 15828834] |
| T-cell | EC50 |
5.66 μM
Compound: pamidronate
|
Effective concentration to activate gammadelta T cells
Effective concentration to activate gammadelta T cells
|
[PMID: 12383012] |
| T-cell | IC50 |
62 μM
Compound: 34
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
|
[PMID: 14711309] |
| T-cell | IC50 |
941 μM
Compound: 34
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
|
[PMID: 14711309] |
| Vero | IC50 |
60 μM
Compound: 5
|
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
|
[PMID: 11300872] |
Pamidronic acid (0.001-1000 µM, 72 h) inhibits the cell viability of osteosarcoma cells POS, HMPOS and COS31, exhibits no cytotoxicity to fibroblasts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:POS, HMPOS and COS31
-
Concentration:0.001-1000 µM
-
Incubation Time:72 h
-
Result:Inhibited the cell viability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Anterior cruciate ligament transection (ACLT)-induced osteoarthritis in rabbits[3]
-
Dosage:3 mg/kg
-
Administration:ear vein injection, once monthly for 14 weeks
-
Result:Increased bone volume fraction (BV/TV), trabecular thickness (TbTh) and trabecular number (TbN).
Reduced the erosion of cartilage surface, increase the content of chondrocytes and matrix.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 40391-99-9
-
性状 Solid
-
分子量 235.07
-
分子式 C3H11NO7P2
-
Color White to off-white
-
SMILES
OC(P(O)(O)=O)(P(O)(O)=O)CCN
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618
溶剤 & 溶解度
H2O : 5 mg/mL (21.27 mM; ultrasonic and warming and heat to 80°C)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (8.51 mM); Clear solution; Need ultrasonic
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Ashton JA, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cellsfrom dogs. Am J Vet Res. 2005 May;66(5):885-92. [Content Brief]
[2]. Xu Y, et al. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Mar 23. [Content Brief]
[3]. Lv Y, et al. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord. 2014 Nov 6;15:371. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.2541 mL | 21.2703 mL | 42.5405 mL | 106.3513 mL |
| 5 mM | 0.8508 mL | 4.2541 mL | 8.5081 mL | 21.2703 mL | |
| 10 mM | 0.4254 mL | 2.1270 mL | 4.2541 mL | 10.6351 mL | |
| 15 mM | 0.2836 mL | 1.4180 mL | 2.8360 mL | 7.0901 mL | |
| 20 mM | 0.2127 mL | 1.0635 mL | 2.1270 mL | 5.3176 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Pamidronic acid 関連分類
HY-B0012 関連分類
Powered by Bioz